Kyverna Therapeutics (KYTX) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Kyverna Therapeutics (KYTX) has outperformed Zura Bio (ZURA) over the past year, losing 9.5% versus a loss of 11.3%. Kyverna Therapeutics is the larger company by market cap ($395.2 million vs $383.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYTX | ZURA |
|---|---|---|
| Share price | $6.39 | $4.00 |
| Market cap | $395.18M | $383.32M |
| 1-day change | +3.40% | -3.15% |
| YTD return | -32.02% | -23.66% |
| 1-year return | -9.49% | -11.31% |
| EPS (TTM) | $-2.93 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.67 | $7.44 |
| 52-week low | $5.96 | $3.15 |
| Distance from 52-week high | -53.26% | -46.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +375.74% | +350.00% |
| Average volume | 903.83K | 1.44M |
| Shares outstanding | 61.84M | 95.83M |
| Employees | 149 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 149 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
KYTX vs ZURA FAQ
Which is bigger, Kyverna Therapeutics or Zura Bio?
Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $395.18M compared with $383.32M for Zura Bio (ZURA).
Which stock has performed better over the past year, KYTX or ZURA?
KYTX returned -9.49% over the past 12 months, compared with -11.31% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Kyverna Therapeutics and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.